Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, cilt.4, sa.2, ss.172-176, 2020 (ESCI)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 4 Sayı: 2
- Basım Tarihi: 2020
- Doi Numarası: 10.14744/ejmo.2020.15578
- Dergi Adı: EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.172-176
- Anahtar Kelimeler: Chemotherapy, ifosfamide, irinotecan, small cell lung cancer, survival, PHASE-II TRIAL, COMPARING CISPLATIN, ETOPOSIDE, CHEMOTHERAPY, CARBOPLATIN, TOPOTECAN, 2ND-LINE, EFFICACY
- Akdeniz Üniversitesi Adresli: Evet
Özet
Objectives: Recurrent and progressive small cell lung cancer (SCLC) has a very poor prognosis, and treatment options are limited. Combination of irinotecan with ifosfamide ( I-I regimen) in SCLC has limited preliminary data. In this study, we aimed to evaluate the efficacy and toxicity of I-I regimen in patients with previously treated SCLC.